ALZN Stock Catalyst: Alzamend Neuro Initiates Phase II Clinical Trial of AL001 at Massachusetts General Hospital

May 28, 2025 · 7:42pm ET

First patient dosed in the trial of the novel lithium-delivery system.

Max move

+176.6%

High of day $9.04

Sparker timei

7:42pm ET

ALZN · May 28, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Alzamend Neuro, Inc. announced on 2025-05-29 Alzamend Neuro announced the dosing of the first patient in its Phase II clinical trial of AL001, a novel lithium-delivery system, at Massachusetts General Hospital.

Alzamend Neuro, Inc. has a free float of 3,125,800 shares and 3,801,600 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time ALZN sparks.

Download Sniper App →

Catch the next ALZN-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →